HAVCR2 and neoplasm: TIM-3 inhibitors are in early clinical development with preliminary studies in mice demonstrating that when TIM-3 inhibitors are used in combination with radiotherapy and PDL-1 inhibitors, this resulted in cessation of tumor growth, though the effects were short lived [12].